- Home
- EXP vs IONS Comparison
EXP vs IONS Comparison
Compare EXP & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXP
- IONS
- Stock Information
- Founded
- EXP 1963
- IONS 1989
- Country
- EXP United States
- IONS United States
- Employees
- EXP N/A
- IONS N/A
- Industry
- EXP Building Materials
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- EXP Industrials
- IONS Health Care
- Exchange
- EXP Nasdaq
- IONS Nasdaq
- Market Cap
- EXP 7.2B
- IONS 6.9B
- IPO Year
- EXP 1994
- IONS 1991
- Fundamental
- Price
- EXP $239.26
- IONS $42.69
- Analyst Decision
- EXP Buy
- IONS Buy
- Analyst Count
- EXP 9
- IONS 15
- Target Price
- EXP $263.67
- IONS $60.13
- AVG Volume (30 Days)
- EXP 398.8K
- IONS 2.2M
- Earning Date
- EXP 07-29-2025
- IONS 07-30-2025
- Dividend Yield
- EXP 0.44%
- IONS N/A
- EPS Growth
- EXP N/A
- IONS N/A
- EPS
- EXP 13.58
- IONS N/A
- Revenue
- EXP $2,286,509,000.00
- IONS $944,050,000.00
- Revenue This Year
- EXP $2.59
- IONS $24.30
- Revenue Next Year
- EXP $5.82
- IONS $7.39
- P/E Ratio
- EXP $17.61
- IONS N/A
- Revenue Growth
- EXP 0.88
- IONS 16.05
- 52 Week Low
- EXP $191.91
- IONS $23.95
- 52 Week High
- EXP $321.93
- IONS $50.43
- Technical
- Relative Strength Index (RSI)
- EXP 61.03
- IONS 53.32
- Support Level
- EXP $224.47
- IONS $41.96
- Resistance Level
- EXP $235.26
- IONS $44.99
- Average True Range (ATR)
- EXP 6.52
- IONS 1.36
- MACD
- EXP 0.01
- IONS -0.05
- Stochastic Oscillator
- EXP 90.09
- IONS 53.63
About EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.